FLGT News and Press, Fulgent Genetics Inc. From 08/05/19

TEMPLE CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of Linda Marsh, Senior Executive Vice President of AHMC Healthcare, Inc. to it...

TEMPLE CITY, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing and Next Generation Sequencing (NGS) solutions, today announced that the company has received...

Genetic testing services providers are in the green after UnitedHealthcare instituted coverage  for Myriad Genetics' GeneSight test for major depressive disorder. More news on: NeoGenomics, Inc., Invitae Corporation, Biocept, Inc., Healthcare stocks news, Stocks on the move, Read...

TEMPLE CITY, Calif., July 22, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its second quarter 2019 financial results after the market closes on Monday August 5, 2019. The...

TEMPLE CITY, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT) and the Parkinson’s Foundation today announced a collaboration on a new genetic testing initiative for individuals living with Parkinson’s Disease (PD). The nation-wide initiative, called PD...

Fulgent Genetics, Inc. (FLGT) Q1 2019 Results Earnings Conference Call May 07, 2019, 04:30 PM ET Company Participants Nicole Borsje - Head of Investor Relations Ming Hsieh - Chief Executive Officer Paul Kim - Chief Financial Officer Conference Call Participants Presentatio...

Fulgent Genetics (NASDAQ: FLGT ): Q1 Non-GAAP EPS of -$0.06 misses by $0.05 ; GAAP EPS of -$0.10 misses by $0.03 . More news on: Fulgent Genetics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

First Quarter 2019 Results : Revenue totals $5.4 million, growing 15% year over year Billable tests delivered total 7,530, growing 63% year over year GAAP loss of $1.9 million, or $0.10 per share Non-GAAP loss of $1.0 million, or $0.06 per share Adjusted EBITDA loss of $712,000 Ca...

Aurora Cannabis (NYSE: ACB ) initiated with Buy rating and C$16.50 (35% upside) price target at Desjardins. Shares up  1%  premarket on the heels of its license deal with EnWave. More news on: Aurora Cannabis Inc., Gilead Sciences, Inc., Tocagen Inc., Healthcare stocks news, Stoc...

TEMPLE CITY, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its first quarter 2019 financial results after the market closes on Tuesday May 7, 2019. The c...